Peerview Internal Medicine Cme/cne/cpe Audio Podcast

Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to:

Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient’s baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better ab

Go online to PeerView.com/GUR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gain the skills you need to adapt your current management protocols to reflect the new treatment reality in chronic lymphocytic leukemia (CLL), utilize novel combinatorial and sequential strategies, and map out the role of emerging cell-based therapies! In this activity, expert hematologist-oncologists provide expert guidance on the transformed nature of modern CLL management, the practice-changing evidence that validated targeted therapy platforms, and the science that is redefining the roles of hematopoietic stem cell transplantation and cellular therapy, including in challenging pretreated CLL settings. Upon completion of this activity, participants should be better able to: Cite current guidelines and evidence on the treatment roles of hematopoietic stem cell transplantation; BTK, PI3K, and BCL-2 inhibitors; monoclonal antibodies; and CAR-T cell therapy in the CLL setting, D

Go online to PeerView.com/EZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Detecting molecular alterations driving the development of specific cancers and then targeting these alterations with matched therapies or combinatorial approaches is now the standard of care for many cancers. HER2 alterations have been identified as key therapeutic targets in breast, gastrointestinal, lung, and other cancers, and targeting these alterations with antibody–drug conjugates (ADCs), antibodies, more specific tyrosine kinase inhibitors, and bispecific antibodies are improving outcomes. In addition to HER2, HER3 represents an emerging target in several cancer types for which novel targeted therapies are being developed, and targeting TROP2 is showing promise as well. Given these treatment advances, biomarker testing to identify patients who may benefit the most from HER2-, HER3-, and TROP2-targeted therapies has never been more important. This activity, based on a rec

Go online to PeerView.com/KPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent clinical developments have transformed the management of graft-versus-host disease (GVHD) and have the potential to increase access to transplants and improve post-HCT outcomes. These advances are centered on the emergence and continued research of several novel modalities, including the BTK inhibitor ibrutinib, JAK inhibitor ruxolitinib, and the T-cell co-stimulation blocking agent abatacept, as well as additional novel strategies being tested in a range of acute and chronic GVHD settings. In this activity from the 2022 Tandem meetings, our expert panelists distill the current evidence on novel therapeutics in the prevention and treatment of GVHD; throughout, they illustrate how and when to integrate novel therapeutics into care, provide guidance on how to prepare for emerging strategies, and offer practical takeaways on the changing nature of GVHD management. Upon compl

Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin’s lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the m

Go online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the presence of immune-related adverse events (irAEs) in some patients linger after the end of therapy and limit the possible subsequent use of ADCs or FGFR inhibitors? To answer these questions, experts in bladder cancer highlight strategies for optimal care of patients in light of current evidence o

Go online to PeerView.com/XNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on refractory ascites and esophageal variceal hemorrhage (EVH) discusses evidence-based strategies to improve patient outcomes. Upon completion of this activity, participants should be better able to: Summarize the prevalence, pathophysiology, and consequences of decompensated cirrhosis and portal hypertension (eg, refractory ascites and EVH), Evaluate the latest evidence for current and emerging approaches to managing patients with refractory ascites and EVH.

Go online to PeerView.com/QWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the current clinical challenges of CLL—including in areas where nurse professionals can have a decisive influence on patient education and the safe delivery of care? This “Clinical Consults” activity, developed in collaboration with the CLL Society, represents a resource for developing modern management strategies in a changing and complicated therapeutic landscape. Throughout, PeerView’s expert speakers present nurse-to-nurse, case-based education and share clinical tools designed to facilitate the effective use of innovative therapeutics in chronic lymphocytic leukemia (CLL) across multiple treatment settings, with the ultimate goal of enhancing patient outcomes. Upon completion of this activity, participants should be better able to: Cite the clinical signs of symptomatic disease, relevant prognostic factors, patient- and disease-related features, and cli

Go online to PeerView.com/CCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss the role of the JAK/STAT pathway in psoriasis, as well as treatment with novel kinase inhibitors for the management of patients with psoriasis. Upon completion of this activity, participants should be better able to: Describe and differentiate targeting of the TYK2, JAK1, JAK2, and JAK3 kinases and the correlation to emerging therapies for the treatment of moderate to severe psoriasis, Summarize recent efficacy and safety data for current and emerging therapies for the treatment of moderate to severe psoriasis, Recommend treatment for patients with moderate to severe psoriasis according to the latest guidelines and clinical evidence, particularly as emerging therapies become available.

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide le

Go online to PeerView.com/GWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to the early-stage setting and transforming the multimodal management of resectable stage I-III NSCLC. Remarkable data have emerged from several immunotherapy trials in perioperative settings and FDA has granted new regulatory approvals for both neoadjuvant and adjuvant immunotherapy regimens, effectively establishing new standards of care in early-stage NSCLC. Still, many questions remain on how to transition these exciting advances to practice and improved patient outcomes in real-world setting. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal timing and duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications hig

Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-

Go online to PeerView.com/HCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors (ICIs) changed the standards of care in the treatment of advanced solid tumors and are now rapidly transitioning into early-stage, curative-intent settings. New regulatory approvals have been recently granted for several ICIs as neoadjuvant and adjuvant treatments for different cancers, and many more studies are under way. This shift is truly needed, as outcomes had plateaued in resectable cancers. To overcome the challenges of conducting ICI clinical trials in early-stage cancers and facilitate more rapid progress, the need for new surrogate measures of efficacy has been widely recognized. Pathologic response assessment of resection specimens after neoadjuvant therapy has emerged as one such new tool, and there is accumulating evidence supporting its relevance and advantages. However, some unanswered questions remain, and there has been a lack o

Go online to PeerView.com/JYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating, progressive neurodegenerative disorder affecting 10% of people over age 65 and increasing in global prevalence. Recent advances in disease-modifying therapies have opened the door to the possibility of treatment approaches that can slow or prevent disease progression and improve patient outcomes. Now, with several anti–amyloid beta (Aβ) monoclonal antibodies in late-stage development, there is hope for families, clinicians, and researchers. The greatest likelihood of treatment success lies in timely diagnosis and early intervention. In this activity, based on a live symposium held at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases in Barcelona, Spain, an international panel of experts will discuss the importance of early recognition and diagnosis of AD and present the latest evidence on validated and emer

Go online to PeerView.com/JNH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert nephrologist examines the pathophysiology of chronic kidney disease (CKD) and the effects of mineralocorticoid receptor overactivation in patients with type 2 diabetes (T2D) to offer practical strategies for identifying which patients with CKD and T2D may benefit from treatment with nonsteroidal MRAs. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of CKD progression and the effects of mineralocorticoid receptor overactivation in patients with T2D, Compare the mechanism of action, potency, selectivity, and physiological distribution of steroidal and nonsteroidal MRAs, Identify patients with CKD and T2D that may derive specific benefit from treatment with nonsteroidal MRAs.

Go online to PeerView.com/TJZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss strategies to optimize patient outcomes in atopic dermatitis and alopecia areata. Upon completion of this activity, participants should be better able to: Appropriately diagnose atopic dermatitis (AD) and alopecia areata (AA) and assess severity to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities, Describe current and emerging treatments for AD and AA in the context of mechanism of action, efficacy and safety profile, dosage and administration, and other factors relevant to clinical use, Utilize available resources to identify and overcome racial and ethnic health disparities in the management of AD and AA and ultimately improve health outcomes in under-represented populations.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it’s on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you

Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those re

Go online to PeerView.com/DTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules symmetrically distributed on the trunk and extremities. PN is defined by intense pruritus lasting ≥6 weeks, history of repeated scratching, and subsequent development of pruritic, elevated, firm, and nodular skin lesions, in a vicious itch–scratch cycle. The intense itch associated with PN leads to sleep disturbances and reduced social participation and work productivity, resulting in a drastically reduced quality of life and psychosocial disturbances. Unfortunately, these issues experienced among patients with PN are further compounded by the lack of effective treatment options. In this activity, based on a recent live educational symposium, a panel of experts addresses real-world questions and dilemmas faced by providers and the PN patients for whom they ca